MPM BioImpact LLC Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001687078

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidHealth TiltHigh Turnover how tags are computed

Q1 2026 · 41 positions · Total reported value $1.29B · Top-10 concentration 49.0% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 81.2% · 7 new · 21 cut · 11 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q1 2026 → Q2 2026): +31.4% · vs SPY +16.6% · Prev Value $1.29B — last quarter positions weighted by this quarter price moves · ranking

In its Q1 2026 13F filing, MPM BioImpact LLC disclosed 41 equity positions with a combined reported value of $1.29B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 49.0% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.

The largest disclosed positions as of Q1 2026 were DBVT ($108.91M), CGEM ($108.68M), AKTS ($86.51M). By sector, the heaviest allocations are Health Care 98.0%, Other 2.0%. Versus the prior quarter, allocation shifted toward Health Care (+1.2pp) and away from Other (-1.2pp).

Versus the prior quarter, MPM BioImpact LLC opened 7 new positions, trimmed 21 and fully exited 11, a turnover rate of 81.2% of positions. The portfolio's overlap with the prior quarter was 61% of names.

The largest new positions opened in Q1 2026 were AKTS ($86.51M), CORT ($39.73M), DNTH ($35.58M).

Of the 11 positions fully exited versus the prior quarter, the largest were MDGL ($56.36M), PTCT ($32.66M), PTGX ($17.42M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q1 2026)

  • AKTS AKTIS ONCOLOGY INC · $86.51M
  • CORT CORCEPT THERAPEUTICS INC · $39.73M
  • DNTH DIANTHUS THERAPEUTICS INC COM · $35.58M
  • MLTX MOONLAKE IMMUNOTHERAPEUTICS · $33.76M
  • TVTX TRAVERE THERAPEUTICS INC · $33.67M
  • CYTK CYTOKINETICS INC · $32.95M
  • FBRX FORTE BIOSCIENCES INC · $25.92M
  • ZYME ZYMEWORKS INC · $14.15M

Fully Exited (vs previous quarter)

  • MDGL MADRIGAL PHARMACEUTICALS INC · prev qtr: $56.36M
  • PTCT PTC THERAPEUTICS INC · prev qtr: $32.66M
  • PTGX PROTAGONIST THERAPEUTICS INC · prev qtr: $17.42M
  • VTYX VENTYX BIOSCIENCES INC · prev qtr: $14.80M
  • RAPT RAPT THERAPEUTICS INC · prev qtr: $13.48M
  • RCKT ROCKET PHARMACEUTICALS INC · prev qtr: $5.57M
  • MAZE MAZE THERAPEUTICS INC COM · prev qtr: $3.36M
  • SRPT SAREPTA THERAPEUTICS INC · prev qtr: $1.51M

Insider Transactions (Form 4)

Latest MPM BioImpact LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

MPM BioImpact LLC, based in Boston, MA, United States, files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 37 positions worth $1.64B in total. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Firm Snapshot

  • Headquarters: BOSTON, MA, United States
  • SEC registration: 801-106989 (status: Approved), registered 2016-01-04
  • Regulatory AUM (Form ADV): $3.56B as of 2026-04-28
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 14 private funds, of which 3 hedge funds

Portfolio Structure

  • 37 positions · $1.64B reported value (Q2 2026)
  • Top 10 holdings = 55.3% of reported value
  • Largest position: CGEM (CULLINAN THERAPEUTICS INC) at 10.8%
  • Average position size: $44.32M

Sector Tilt

  • Health Care 98.7%
  • (classified holdings cover 99% of value)

Quarterly Activity

  • Q2 2026: 7 new, 7 added, 21 reduced, 11 exited
  • 2 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 98.0%
Other 2.0%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 5.21M $108.91M 8.41%
8.41%
Add
2 7.65M $108.68M 8.39%
8.39%
Hold
3 4.84M $86.51M 6.68%
6.68%
New
4 1.41M $53.03M 4.09%
4.09%
Hold
5 2.39M $52.58M 4.06%
4.06%
Reduce
6 1.66M $52.31M 4.04%
4.04%
Hold
7 506.78K $49.28M 3.81%
3.81%
Hold
8 1.31M $44.19M 3.41%
3.41%
Hold
9 985.70K $39.73M 3.07%
3.07%
New
10 3.30M $39.35M 3.04%
3.04%
Hold
11 423.98K $35.58M 2.75%
2.75%
New
12 588.71K $34.23M 2.64%
2.64%
Add
13 1.81M $33.76M 2.61%
2.61%
New
14 1.13M $33.67M 2.60%
2.60%
New
15 1.46M $33.47M 2.58%
2.58%
Add
16 500.00K $32.95M 2.54%
2.54%
New
17 1.34M $31.32M 2.42%
2.42%
Hold
18 10.68M $27.98M 2.16%
2.16%
Hold
19 1.00M $25.92M 2.00%
2.00%
New
20 206.40K $25.73M 1.99%
1.99%
Hold
21 1.41M $25.53M 1.97%
1.97%
Hold
22 767.04K $24.97M 1.93%
1.93%
Hold
23 1.67M $24.50M 1.89%
1.89%
Reduce
24 2.36M $23.48M 1.81%
1.81%
Add
25 329.75K $23.13M 1.79%
1.79%
Hold
26 1.80M $22.86M 1.76%
1.76%
Hold
27 1.37M $22.39M 1.73%
1.73%
Reduce
28 1.18M $19.36M 1.50%
1.50%
Hold
29 93.07K $18.61M 1.44%
1.44%
Reduce
30 2.59M $17.77M 1.37%
1.37%
Reduce
31 733.97K $17.29M 1.33%
1.33%
Add
32 943.80K $16.97M 1.31%
1.31%
Hold
33 212.18K $15.48M 1.20%
1.20%
Reduce
34 565.25K $14.15M 1.09%
1.09%
New
35 88.05K $14.04M 1.08%
1.08%
Hold
36 649.87K $12.71M 0.98%
0.98%
New
37 1.85M $12.57M 0.97%
0.97%
Hold
38 107.27K $11.94M 0.92%
0.92%
Add
39 2.24M $5.47M 0.42%
0.42%
New
40 391.92K $1.47M 0.11%
0.11%
New
41 1.21M $1.01M 0.08%
0.08%
Reduce

FAQ

What did MPM BioImpact LLC buy in 2026-Q1?

In its 2026-Q1 13F filing, MPM BioImpact LLC reported 41 equity positions worth $1.29B in aggregate; its largest disclosed positions were DBVT ($108.91M), CGEM ($108.68M), AKTS ($86.51M).

How large is MPM BioImpact LLC's portfolio?

MPM BioImpact LLC reported $1.29B of long equity holdings across 41 positions as of 2026-Q1. Top-10 holdings account for 49.0% of reported value.

What is MPM BioImpact LLC's investment style?

HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/mpm-bioimpact/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →